Researchers found that cytoreductive surgery combined with multimodal therapies significantly improved overall survival and progression-free survival in patients with advanced ovarian, colorectal, and gastric cancers. Analyzing data from 13 studies involving nearly 4,000 patients, the experimental group showed a 14% decrease in mortality risk and enhanced survival rates, although associated with a higher risk of grade 3 or worse adverse events. These results emphasize the potential benefits of individualized treatment approaches for specific cancer types.
Review by Yuan X, Liang H (…) Chen Z et 3 al. in World J Surg Oncol
© 2025. The Author(s).